Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
36 participants
INTERVENTIONAL
2013-09-30
2016-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer
NCT02229058
Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
NCT04047953
Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer
NCT04675866
Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer
NCT03137004
Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer
NCT03286244
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
albumin-bounded paclitaxel plus S-1
arm 1:albumin-bounded paclitaxel 200mg iv d1 and S-1 80mg/m2/d po d1-10, repeated every 2 weeks,up to 9 cycles,then S-1 as single agent to treat to disease progression
albumin-bounded paclitaxel
200mg iv d1, repeat every 2 weeks,until disease progression,or up to 9 cycles
S-1
40mg/m2 po, bid,d1-10,repeated every 2 weeks until disease progression
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
albumin-bounded paclitaxel
200mg iv d1, repeat every 2 weeks,until disease progression,or up to 9 cycles
S-1
40mg/m2 po, bid,d1-10,repeated every 2 weeks until disease progression
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult patients \>=18 years of age
* Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-2;
* At least have one measurable disease(according to RECIST)
* Adequate bone marrow,renal and liver function
Exclusion Criteria
* Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese Academy of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lin Yang
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lin Yang, MD
Role: PRINCIPAL_INVESTIGATOR
Department of medical oncology,Cancer hospital and institute,CAMS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Medical Oncology,Cancer Hostpital and Institute,CAMS
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CH-GI-037-nab
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.